

Tailored therapeutic release from polycaprolactone-silica hybrids for the treatment of osteomyelitis:
antibiotic rifampicin and osteogenic silicates - Supplementary data




Figure S1: Weight loss in α MEM for the four hybrid formulations, monitored over the course of two weeks. No variation associated with different formulations was assessed ($p \gg 0.05$)




Figure S2: pH variation in α MEM for the four hybrid formulations, monitored over the course of two weeks. The standard pH of α MEM is highlighted (7.4). No significant variation from 7.4 was assessed, regardless of the formulation ($p \gg 0.05$).